Cancer-induced liver inflammation impairs T cell infiltration into tumors, reducing the effectiveness of immunotherapy. The study identifies serum amyloid A (SAA) proteins as key mediators of this effect, suggesting potential therapeutic targets to improve immunotherapy outcomes.